Post‐disclosure distress among racial and ethnic groups in a preclinical AD trial

Abstract

AbstractINTRODUCTIONTrialists need a thorough understanding of whether reactions to Alzheimer's disease (AD) biomarker information differ among racial and ethnic groups in preclinical AD trials.METHODSWe used data from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease Study to analyze cognitively unimpaired participants’ responses on the Impact of Event Scale (IES) 24 to 72 hours after amyloid disclosure. We fit a linear regression model to test whether mean IES scores differed among participants from specific racial and ethnic groups. We considered potential effect modification by amyloid status.RESULTSReactions to disclosure did not significantly differ among participant groups based on self‐reported race and ethnicity. Although the results were not significant when stratified by amyloid status, all racial and ethnic groups except for participants self‐reporting Hispanic/Latino ethnicity were observed to have higher mean IES in the elevated amyloid group.DISCUSSIONThese results support continued use of current disclosure methods in preclinical AD trials.